Orbit of Care in Indian T2D with CV Risk: Practice Update & Spotlight on Smart Application of Dapagliflozin & Sitagliptin FDC

In India, type 2 diabetes(T2D) clusters with cardiovascular risk and earlier age than in Western populations, mainly driven by visceral adiposity that fuels insulin resistance and β-cell failure through inflammatory cytokines like TNF-α and IL-6. With nearly 50% of T2D patients presenting complications at diagnosis and accelerated atherosclerosis already underway, managing hyperglycemia alone is no longer sufficient. Contemporary practice demands an orbit of care - simultaneous glycemic, metabolic, cardiac and renal protection from the outset, to break the microvascular and macrovascular complications trajectory early and durably.¹

Mechanistic Synergy: Dapagliflozin & Sitagliptin FDC as Complementary Pathways in T2D

Dapagliflozin lowers glucose independently of insulin by promoting urinary glucose excretion, while reducing weight and blood pressure, combined with established cardio-renal protection. Sitagliptin stabilizes incretins (GLP-1, GIP) to enhance glucose-dependent insulin secretion with low hypoglycemia risk; early initiation preserves beta-cell function by mitigating glucotoxicity and sustaining endogenous insulin production. These agents target distinct pathophysiological defects through actions on kidney and incretin pathways, indirectly protecting against insulin resistance and beta-cell decline in the long run, regulated by non-overlapping mechanisms.^2,3,4

Dapagliflozin & Sitagliptin FDC: Indian real-world evidence of the last three years at a glance:

Glycemic Control in T2D across age groups with Dapagliflozin & Sitagliptin FDC: A real-world EMR-based study (n=3,112) evaluated Dapagliflozin & Sitagliptin FDC across broad groups of Indian adults with T2D. Overall, HbA1c fell by 1.31% (from 9.29% to 7.98%; P< 0.001) over three months, with consistent reduction in fasting glucose (from 163.91 to 134.17 mg/dL) and postprandial glucose (from 244.22 to 197.97 mg/dL) across all age strata (25–44, 45–60, and >60 years). The Dapagliflozin & Sitagliptin FDC was well tolerated without added hypoglycemia risk. ⁵

Effect of Dapagliflozin & Sitagliptin FDC on CV risk factors in high-risk T2D patients: The BRIDGE-DS multicenter study (n=1,091) in Indian T2D patients with ASCVD or high cardiovascular risk treated with Dapagliflozin 10mg & Sitagliptin 100mg FDC demonstrated HbA1c reduction of 1.5% (from 8.9% to 7.4%, p<0.001), FPG reduction of 43.7 mg/dL, and PPG reduction of 72.0 mg/dL over 3 months. The study reported improvements in modifiable cardiovascular risk factors, including weight (BMI reduction from 28.6 to 27.8 kg/m²), systolic blood pressure (from 150.5 to 131.5 mmHg), and lipid parameters values (TC from 234.3 to 192.7 mg/dL; HDL-C from 46 to 49.4 mg/dL). These data support Dapagliflozin & Sitagliptin FDC, a comprehensive, evidence-based option for Indian T2D patients with cardiovascular risk. ⁶

Dapagliflozin & Sitagliptin FDC - Potent glycemic lowering in treatment-naive T2D: Another Indian study including 358 Indian T2D patients evaluated dapagliflozin-sitagliptin FDC with mean baseline HbA1c of 8.9%. At 12 weeks, HbA1c significantly decreased from 8.8 % to 7.2%(p < 0.0001), FPG reduced from 178.8 to 124.0 mg/dL, and PPG decreased from 273.9 to 176.0 mg/dL. No serious adverse events were reported, supporting the combination of Dapagliflozin & Sitagliptin FDC as an effective, well-tolerated option for T2D management in India. ⁷

These Indian real-world evidences published over the last three years further reiterate that Dapagliflozin & Sitagliptin FDC have the potential to offer an orbit of care in high CV risk T2D, with effective reductions in glycemic, metabolic, and cardiovascular risk factors, thereby reducing the risk of diabetes-related complications.

Smart Clinical Application: When to Consider Dapagliflozin & Sitagliptin FDC?

The Indian Cardiologists' Consensus (n=98 cardiologists) recommends Dapagliflozin & Sitagliptin FDC for T2D patients with HbA1c ≥8%, established ASCVD, heart failure, CKD, elderly T2D, or those uncontrolled on metformin. The BRIDGE-DS HF cohort further supports, Dapagliflozin & Sitagliptin FDC in T2D with concurrent HF, showing NT-pro BNP reduction and eGFR improvement alongside glycemic control. This combination aligns with guideline-directed therapy when SGLT2i is indicated for cardio-renal protection and DPP4i is preferred for glycemic durability with low hypoglycemia risk.^8,9

Figure: Orbit of Care in T2D with CV Risk: Potential of Dapagliflozin & Sitagliptin FDC

Take Home Pointers

• In India, T2D converges with high cardiovascular risk at younger age, necessitating simultaneous glycemic, metabolic, cardiac, and renal protection early from the time of T2D diagnosis.
• Dapagliflozin & Sitagliptin FDC combines complementary SGLT2i and DPP4i mechanisms to deliver meaningful HbA1c, FPG, and PPG reductions, while also improving weight, blood pressure, and broader cardiometabolic risk markers with good tolerability in Indian real-world studies, providing a comprehensive orbit of care in T2D.

• Emerging Indian evidence and cardiology consensus support early use of Dapagliflozin & Sitagliptin FDC in high-risk T2D patients, particularly those with HbA1c ≥8%, ASCVD, heart failure, CKD, elderly T2D, or inadequate control on Metformin, to achieve durable glycemic and cardio-renal protection.

Abbreviations: ASCVD — Atherosclerotic Cardiovascular Disease, BMI — Body Mass Index, CKD — Chronic Kidney Disease, DPP4i — Dipeptidyl Peptidase-4 Inhibitor, eGFR — Estimated Glomerular Filtration Rate, EMR — Electronic Medical Records, FBG — Fasting Blood Glucose, FDC — Fixed-Dose Combination, GIP — Glucose-Dependent Insulinotropic Polypeptide, GLP-1 — Glucagon-Like Peptide-1, HbA1c — Glycated Hemoglobin, HF — Heart Failure, IL-6 — Interleukin-6, NT-proBNP — N-Terminal Pro-B-Type Natriuretic Peptide, PPG — Postprandial Glucose, SGLT2i — Sodium-Glucose Cotransporter-2 Inhibitor, T2D — Type 2 Diabetes, TNF-α — Tumor Necrosis Factor-alpha